Morning Overview on MSN
Experimental prostate cancer drug shrinks tumors in early clinical trial
Several experimental prostate cancer drugs have produced striking results in early-stage clinical trials, with at least one ...
(NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA ® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI ® ...
PHOENIX — Prostate cancer is one of the most common cancers in the world. While many prostate cancers grow slowly and remain localized, other types are aggressive and spread quickly. That's why Dr.
An ultrasound-based treatment for prostate cancer showed better safety and operative metrics versus robotic radical ...
Prostate cancer is one of the leading causes of cancer-related death in men, and some experts project the number of cases to rise over the coming decades. But in a recent Urologic Oncology article, ...
A new immunotherapy drug has demonstrated early promise in a recent prostate cancer clinical trial. The drug, called VIR-5500, is a "masked T-cell engager". This type of immunotherapy ignites our own ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results